(Press-News.org) An ultra-fast, 320-detector computed tomography (CT) scanner can accurately sort out which people with chest pain need – or don't need – an invasive procedure such as cardiac angioplasty or bypass surgery to restore blood flow to the heart, according to an international study. Results of the study, which involved 381 patients at 16 hospitals in eight countries, are scheduled to be presented at the European Society of Cardiology Congress in Munich, Germany, on August 28.
"The CORE 320 study is the first prospective, multicenter study to examine the diagnostic accuracy of CT for assessing blockages in blood vessels and determining which of those blockages may be preventing the heart from getting adequate blood flow," says Joao A. C. Lima, M.D., senior author of the study and professor of medicine and radiology at the Johns Hopkins University School of Medicine. "We found an excellent correlation in results when we compared the 320-detector CT testing with the traditional means of assessment using a stress test with imaging and cardiac catheterization."
The study findings, says Lima, would apply to people who have chest pain but are not having a heart attack. Many people in that situation are sent to a cardiac catheterization laboratory for further evaluation with angiography, an invasive test to look for blockages in the coronary arteries using dye and special X-rays. About 30 percent of people who have such catheterization are found to have minimal disease or no blockage requiring an intervention to open or bypass the vessel.
Lima explains that a nuclear medicine stress test with imaging, known as SPECT, shows reduced blood flow to the heart without indicating the number or specific location of blockages.
The 381 patients who completed the study had traditional SPECT tests and invasive angiography. They also had two types of tests with a non-invasive 320-detector CT scanner. In the first CT test, the scanner was used to see the anatomy of vessels to assess whether and where there were blockages. That test is known as CTA, in which the "A" stands for angiography. Then, in a second CT test with the same machine, patients were given a vasodilator, a medicine that dilates blood vessels and increases blood flow to the heart in ways similar to what happens during a stress test. The second test is called CTP, with the "P" standing for perfusion.
According to lead author Carlos E. Rochitte, M.D., a cardiologist at the Instituto do Coracao in Sao Paulo, Brazil, "We found that the 320-detector CT scanner allowed us to see the anatomy of the blockages as well as determine whether the blockages were causing a lack of perfusion to the heart. We were therefore able to correctly identify the patients who needed revascularization within 30 days of their evaluation."
"Many patients are sent for an angioplasty when they may not need it. Our ultimate goal is to have more certainty about which patients having chest pain – without evidence of a heart attack – need an invasive procedure to open an arterial blockage," says cardiologist Richard George, M.D., assistant professor of medicine at the Johns Hopkins University School of Medicine and a co-author of the study.
"The CTP test added significant information about the patients' conditions and boosted our ability to identify those whose blockages were severe enough to reduce blood flow to the heart," adds George, who developed the CTP method with Lima.
The 320-detector CT provides a complete picture of the heart by making just one revolution around the body. The researchers say the two tests combined – CTA and CTP – still produce less radiation than a scan with the 64-detector in widespread use today.
"In our study, the amount of radiation exposure to patients from the two 320-detector CT scanner tests was half the amount they received as a result of the traditional evaluation methods – the angiogram and nuclear medicine stress test combined," says Lima.
The researchers will continue to follow the patients in the study for up to five years, looking for any heart-related events such as heart attacks, as well as hospital admissions, procedures or surgeries.
Hospitals that participated in the CORE 320 study are located in the United States, Germany, Canada, Brazil, the Netherlands, Denmark, Japan and Singapore. Images obtained during the study were evaluated in core laboratories at Johns Hopkins and at the Brigham and Women's Hospital in Boston. The study was sponsored by Toshiba Medical Systems.
Johns Hopkins researchers collaborated with Toshiba on the development of the 320-detector CT scanner used in the study. In 2007, Johns Hopkins was one of three sites that participated in worldwide beta testing of the scanner that served as the prototype of the 320-detector system. Feedback provided by Johns Hopkins researchers was instrumental in the development of the scanner, which is now the only 320-detector CT scanner on the market.
INFORMATION: END
Cases of one of the world's deadliest diseases—tuberculosis—are rising at an alarming rate, despite widespread vaccination. Reasons for the ineffectiveness of the vaccine, especially in regions where this infectious disease is endemic, as well as arguments for replacing the existing vaccine with novel synthetic vaccines, are presented in a review published online August 28th in Trends in Molecular Medicine.
"Tuberculosis is a global health threat, and it is a highly communicable disease that may influence practically anyone and everyone," says senior author Javed Agrewala ...
Munich, Germany – August 28 2012: Recommendations for the practical management of CRT patients have been set out for the first time in an international consensus statement on cardiac resynchronization therapy (CRT) in heart failure.
The 2012 Expert Consensus Statement on Cardiac Resynchronization Therapy (CRT) in Heart Failure: Implant and Follow-up Recommendations and Management was developed by the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society (HRS) in the US, and will be published ...
Munich, Germany – August 28 2012: Surgical ablation of the left atrium to restore regular sinus rhythm is widely used in patients with atrial fibrillation (AF) undergoing cardiac surgery. The restoration of sinus rhythm might decrease the risk of heart failure, stroke and death during long-term follow up.(1) However, despite its promise, this theoretical benefit has never been clearly established - previous randomised studies have been small and performed in a selected group of patients undergoing mitral valve surgery.
Now, a multicentre study of surgical ablation (using ...
Munich, Germany – August 28 2012: Lifelong anticoagulation is necessary for the prevention of stroke in patients with rhythm disturbances and with mechanical valves. Patients who have a coronary stent implanted also need the antiplatelet drugs aspirin and clopidogrel to prevent the rare but lethal complication of stent thrombosis. For patients taking oral anticoagulant drugs (for atrial fibrillation or mechanical valve) who also have to undergo coronary stenting, the optimal antithrombotic treatment is still unknown, even though the use of all three drugs (oral anticoagulants, ...
Munich, Germany – August 28 2012: Catheter ablation for atrial fibrillation (Afib) is safe and suppresses arrhythmia recurrences in 74% of patients after a single procedure, according to results from the one-year follow-up of the Atrial Fibrillation Ablation Pilot Study, the first European registry to evaluate the real-life epidemiology of catheter ablation for AFib. The survey also showed that arrhythmia-related symptoms such as palpitations, shortness of breath, fatigue or dizziness - present in 86% of patients before the ablation - were significantly reduced.
The findings ...
Munich, Germany – August 28 2012: A non-invasive imaging strategy which integrates non-invasive CT angiography (CTA) and CT myocardial perfusion imaging (CTP) has robust diagnostic accuracy for identifying patients with flow-limiting coronary artery disease in need of myocardial revascularisation, according to results of the CORE320 study presented here today by Dr Joao AC Lima from Johns Hopkins Hospital, Baltimore, USA.
The CORE320 study is a prospective multicentre international trial which evaluated the diagnostic accuracy of combined non-invasive CTA and CTP as compared ...
August 28, 2012, Shenzhen, China – The international research team led by Chinese Academy of Agricultural Sciences and BGI have completed the genome sequence and analysis of a diploid cotton-- Gossypium raimondii. The cotton genome provides an invaluable resource for the study and genetic improvement of cotton quality and output, and sheds new lights on understanding the genetic characteristics and evolutionary mechanism underlying cotton and its close relatives. The study was published online in Nature Genetics. (http://www.nature.com/ng/journal/vaop/ncurrent/full/ng.2371.html).
Cotton, ...
Munich, Germany – August 28 2012: Patients with stable coronary artery disease (CAD) had a lower need for urgent revascularisation when receiving fractional flow reserve (FFR)-guided PCI plus the best available medical therapy (MT) than when receiving MT alone. The results, from a final analysis of the FAME 2 trial, were presented today during a Hot Line session of ESC Congress 2012 in Munich. Treatment guided by fractional flow reserve assessment helped reduce the risk of urgent revascularisation by a factor of eight.
The FAME 2 (FFR-Guided Percutaneous Coronary Intervention ...
Disruptions to the circadian rhythm can affect the growth of blood vessels in the body, thus causing illnesses such as diabetes, obesity, and cancer, according to a new study from Linköping University and Karolinska Institutet in Sweden.
The circadian rhythm is regulated by a "clock" that reacts to both incoming light and genetic factors.
In an article now being published in the scientific journal Cell Reports, it is demonstrated for the first time that disruption of the circadian rhythm immediately inhibit blood vessel growth in zebra fish embryos.
Professor Yihai Cao ...
Global platelet reactivity is more effective than responsiveness to clopidogrel in identifying acute coronary syndrome (ACS) patients at high risk of ischemic events, according to research presented at ESC Congress 2012.
The results from the RECLOSE 2-ACS study were presented by Dr Rossella Marcucci from the University of Florence.
The Responsiveness to Clopidogrel and Stent thrombosis 2 – ACS (RECLOSE 2-ACS) study is a prospective, observational, referral centre cohort study of 1,789 patients with acute coronary syndromes undergoing percutaneous coronary intervention ...